UNSPSC 51332843: Chlorpromazine phenolphthalinate

This classification denotes a phenothiazine and antipsychotic agent C20H16O4.C17H19ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5PYC320IMD, chemically known as benzoic acid, 2-(bis(4-hydroxyphenyl)methyl)-, compd. with 2-chloro-n,n-dimethyl-10h-phenothiazine-10-propanamine (1:1), but more generally known as chlorpromazine phenolphthalinate, which bears US NIH Compound Identifier 2726. Most nations, for tariff and trade purposes, schedule chlorpromazine phenolphthalinate under HS 29343090 and SITC 51578.

As of Q4 2014, CHLORPROMAZINE PHENOLPHTHALINATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.C1CCC(C(C1)C(C2CCC(CC2)O)C3CCC(CC3)O)C(=O)O.

UNSPSC 51332843 Chlorpromazine phenolphthalinate is a Commodity code that does not align with the recent state and local contract opportunities posted under it. The most current solicitations show state and local governments procuring naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are chlorpromazine phenolphthalinate or closely related pharmaceutical compounds. The code shows little relevant recent activity, and the mismatch between the code's nominal scope and the actual goods being solicited suggests either miscategorization in source systems or dormant activity under this specific Commodity designation.

The three recent opportunities span different jurisdictional types and procurement stages. Seminole County, Florida issued an IFB on June 30, 2026, for annual purchases of naloxone and drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023. Texas Health and Human Services Commission posted an RFI on April 3, 2026, seeking vendor capabilities for a direct-to-manufacturer pharmacy program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers to participating state and local facilities including Oregon. Geographic activity centers on Florida, Texas, and Minnesota, with multi-state reach through the MMCAP cooperative vehicle.